The purpose of this study is to assess the prevalence of major structural birth defects in infants of female participants with ulcerative colitis (UC) or Crohn's disease (CD) exposed to vedolizumab during pregnancy, compared to participants with UC or CD exposed to other biologic agents.
Who can participate
Age range18 Years ā 44 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Is a currently pregnant woman with UC or CD,
ā. Has exposure to Entyvio or other biologic agents at any dose, and at any time from first day of LMP,
ā. Has enrolled no later than 19 completed weeks after LMP.
ā. Agrees to the conditions and requirements of the study including the interview schedule, release of medical records, and the physical examination of live born infants.
ā. Is a currently pregnant woman with no chronic disease.
ā. Has no exposure to any biological agent and at any time from first day of LMP,
ā. Has enrolled no later than 19 completed weeks after LMP.
ā. Agrees to the conditions and requirements of the study including the interview schedule, release of medical records, and the physical examination of live born infants.
Exclusion criteria
ā. Is greater than (\>) 19 completed weeks gestation prior to enrollment,
ā. Has first contact with OTIS after prenatal diagnosis of any major structural defect,
ā. Has enrolled in this registry with a previous pregnancy,
ā. Has had an exposure to the known or suspected human teratogens: Chlorambucil. Cyclophosphamide, Mycophenylate mofetil.
What they're measuring
1
Major Structural Birth Defects Identified in Infants After Birth